CPC Main Group
A61P 5/00 Drugs for disorders of the endocrine system
Filing statistics
CPC A61P 5/00 belongs to the parent subclass A61P, which recorded 1,315,178 patent applications worldwide between 2013 and 2023. Annual filings grew from 98,407 in 2013 to 103,748 in 2023 (+5%), peaking at 144,884 applications in 2020. The most active applicants in class A61 are PHILIPS ELECTRONICS (20,621 applications), NOVARTIS (15,792 applications) and ROCHE (14,303 applications).
Source: EPO PATSTAT, worldwide filings
8 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/10 of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 5/14 of the thyroid hormones, e.g. T3, T4
- A61P 5/18 of the parathyroid hormones
- A61P 5/24 of the sex hormones
- A61P 5/38 of the suprarenal hormones
- A61P 5/48 of the pancreatic hormones
Top Applicants
Top 10 applicants by patent filingsfor class A61, 2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 20,621
- NOVARTIS CH 15,792
- ROCHE CH 14,303
- COVIDIEN US 13,862
- HARVARD UNIVERSITY US 13,454
- UNIVERSITY OF CALIFORNIA US 12,798
- P&G (PROCTER & GAMBLE COMPANY) US 12,140
- L'OREAL FR 11,800
- OLYMPUS CORPORATION JP 9,894
- BOSTON SCIENTIFIC SCIMED US 9,513